Pharmacologic MCAS treatment (H1/H2 antihistamines, cromolyn, leukotriene antagonists, omalizumab for chronic urticaria, and a few emerging targeted biologics) has the strongest evidence base. Dietary and nutraceutical interventions (DAO enzyme, vitamin C, quercetin, luteolin, low-histamine diet) have moderate evidence in narrow indications but lack the RCT base for MCAS specifically. The supplements Andra promotes are mostly safe at typical doses but should not replace mainstream MCAS treatment.
01Tier 1 — Mainstream MCAS treatment
| Intervention | Evidence rating | Trial | Outcome |
|---|---|---|---|
| H1 antihistamines (cetirizine, loratadine, hydroxyzine, ketotifen) | 4 | Systematic review (PMID 26095756); Weiler 413-patient series (PMID 28262205) | ~70% of MCAS patients report at least partial symptom improvement on H1 + H2 combination.[63][75] |
| H2 antihistamines (famotidine, ranitidine) | 4 | Same as above | Adjunct to H1; particularly useful for GI symptoms.[63][75] Famotidine activates the vagal inflammatory reflex (PMID 35578169).[74] |
| Cromolyn sodium (oral) | 3 | Open-label pediatric and adult series; case series in MCAS (PMID 30964355, 41728426) | Effective for GI-dominant MCAS; pediatric high-dose oral cromolyn series in ME/CFS showed benefit in subset.[26][65] |
| Leukotriene receptor antagonists (montelukast) | 3 | Open-label; included in most MCAS step-therapy | Useful for respiratory and skin flares.[30] |
| Omalizumab (anti-IgE) | 4 | Large RCTs in chronic urticaria (separate from MCAS, but mechanistically overlapping) | FDA-approved for chronic spontaneous urticaria; off-label for MCAS with elevated IgE.[30] |
| Aspirin (low-dose) | 3 | Open-label, Weiler series | Useful in patients whose main mediator is PGD2 (cyclooxygenase-blockable); can also cause non-allergic reactions.[75] |
Swipe table →
02Tier 2 — Nutraceuticals and supplements with positive but limited evidence
| Intervention | Evidence rating | Best evidence | Evidence note |
|---|---|---|---|
| Oral DAO enzyme (porcine kidney extract, 4.5 mg) | 3 | RCT in episodic migraine (PMID 29475774); chronic spontaneous urticaria (PMID 29698966); fibromyalgia (PMID 37892588) | Trials typically dosed oral DAO ~15–20 min; useful when AOC1 polymorphisms or low serum DAO are documented.[84][83][82] |
| Vitamin C | 3 | Hagström 1983 depletion study (PMID 8951736); Johnston 1992 (PMID 1578094); review of bronchoconstriction (PMID 25788952) | Drops whole-blood histamine in depleted subjects; helps exercise-induced bronchoconstriction. Less reliable if baseline is normal.[132][135][46] |
| Quercetin | 3 | Mechanistic in vitro; in vivo rat PCA inhibition; small human niacin-flush study (PMID 18831918); comprehensive reviews (PMID 40362785, 41305557) | Often combined with bromelain or vitamin C for absorption; modest direct MCAS evidence but reasonable safety profile.[89][86][85] |
| Luteolin | 2 | Open-label pediatric autism pilot (PMID 23688534); mechanistic | Limited MCAS RCT data.[88] |
| Nettle (Urtica dioica) | 2 | In vitro H1 receptor antagonism, mast-cell tryptase inhibition (PMID 19140159); mechanistic only | No MCAS clinical trial.[31] |
| Low-histamine diet | 3 | Positive in CSU (PMID 34826140), atopic dermatitis subgroup (PMID 40431369), pediatric CSU (PMID 40880715), and natural food chemicals review (PMID 39236849) | 4–6 week elimination then structured reintroduction. But PMID 37648152 (DBPC histamine challenge) shows most suspected HIT patients do not react to histamine under blinded conditions — suggests over-diagnosis.[18][119][120][118] |
Swipe table →
03Tier 3 — Speculative / low-evidence
| Intervention | Evidence rating | Best evidence | Evidence note |
|---|---|---|---|
| Vitamin E | 2 | Mechanistic; some evidence for combined antioxidant effect on histamine signaling | Often combined with vitamin C; no MCAS-specific RCT. |
| Beef kidney as DAO source | 1 | In vitro DAO assay (PMID 31655856) measures activity in food matrices; no quantification of cooked beef kidney DAO activity | Beef kidney is nutrient-dense (selenium, B12, copper, B6) but the "active DAO survives digestion" claim is unproven.[59] |
| Sleep / circadian work | 3 | Circadian variation in serum tryptase (PMID 15813817); mast-cell-sleep review (PMID 41915304) | Mechanistic + animal data; very limited human MCAS sleep trials.[117][116] |
| Stress reduction / CRH reduction | 3 | CRH → mast cell → intestinal permeability (PMID 24153250) | Real mechanism; no MCAS-specific clinical trial but plausibly useful.[110] |
| Limbic retraining (DNRS / Annie Hopper) | 1 | None in MCAS specifically | No primary MCAS trial of the program. Used widely in mold/CIRS community. |
| Organotherapy | 1 | Historical (PMID 40396860) | No modern trial. |
| Cell salts (biochemic) | 1 | Public-complementary-medicine factor analysis (PMID 10859600) | No peer-reviewed evidence for MCAS or any related indication. |
Swipe table →
04Cross-cutting intervention notes
- H1 + H2 combination is the bedrock of mainstream MCAS therapy. Weiler reported that most MCAS patients achieve meaningful control with H1 + H2 + mast-cell stabilizers (cromolyn or ketotifen), with biologics reserved for refractory cases.[75]
- Tryptase measurement is the diagnostic test; symptom improvement is the response test. A 20% rise over baseline during a flare is the consensus-1 biochemical criterion.[5]
- Dietary intervention of HIT subgroup — works; of MCAS subgroup — less clear; of mastocytosis — sometimes contraindicated (e.g., trigger avoidance may be impossible).
- DAO supplementation is the highest-evidence nutraceutical in the Andra protocol. Three RCTs in three distinct indications.[82][83][84]
- Vitamin C is the second-most evidence-supported; effect size is modest and depends on baseline.[132][134][135]
- Quercetin is third; mostly mechanistic and indirect evidence.[86][89]
- Nettle and luteolin are reasonable adjuncts but lack MCAS RCTs.
05Notes
- Andra's protocols generally emphasize stacking supplements early; mainstream MCAS literature emphasizes H1/H2 first, then cromolyn/leukotriene, then biologics. The two converge on antihistamines as foundation; diverge on how quickly to escalate to nutraceuticals.
- The "beef kidney as DAO source" claim deserves explicit testing: cooking temperatures typically exceed DAO thermal stability, and the DAO that survives digestion is reduced by gut pH and pancreatic proteases. A clinical trial would answer this; one has not been done.
- The cleanest single signal in the nutraceutical evidence: DAO enzyme supplementation for episodic migraine (PMID 29475774, 2013 RCT, positive).[84]
06Connections
Neighborhood · 6 linked entriesOpen full map →
07Sources
- PubMed 26095756PubMed 26095756
- PubMed 28262205PubMed 28262205
- PubMed 35578169PubMed 35578169
- PubMed 30964355PubMed 30964355
- PubMed 29475774PubMed 29475774
- PubMed 29698966PubMed 29698966
- PubMed 37892588PubMed 37892588
- PubMed 8951736PubMed 8951736
- PubMed 1578094PubMed 1578094
- PubMed 25788952PubMed 25788952
- PubMed 18831918PubMed 18831918
- PubMed 40362785PubMed 40362785
- PubMed 23688534PubMed 23688534
- PubMed 19140159PubMed 19140159
- PubMed 34826140PubMed 34826140
- PubMed 40431369PubMed 40431369
- PubMed 40880715PubMed 40880715
- PubMed 39236849PubMed 39236849
- PubMed 37648152PubMed 37648152
- PubMed 31655856PubMed 31655856
- PubMed 15813817PubMed 15813817
- PubMed 41915304PubMed 41915304
- PubMed 24153250PubMed 24153250
- PubMed 40396860PubMed 40396860
- PubMed 10859600PubMed 10859600
- PubMed 31470118PubMed 31470118
- PubMed 34209583PubMed 34209583
- PubMed 25889530PubMed 25889530
- PubMed 36069791PubMed 36069791
- PubMed 30961835PubMed 30961835
- PubMed 41728426PubMed 41728426
- PubMed 41305557PubMed 41305557
- PubMed 15050101PubMed 15050101
- PubMed 42346839PubMed 42346839
08Entry history
Latest content update.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.